Hims & Hers Health, Inc. (NYSE:HIMS) CEO Sells $987,701.40 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 36,460 shares of the stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $27.09, for a total value of $987,701.40. Following the transaction, the chief executive officer now directly owns 27,918 shares of the company’s stock, valued at approximately $756,298.62. This trade represents a 56.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Andrew Dudum also recently made the following trade(s):

• On Tuesday, January 21st, Andrew Dudum sold 300 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.00, for a total value of $9,000.00.
• On Monday, December 16th, Andrew Dudum sold 78,127 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.62, for a total transaction of $2,314,121.74.
• On Monday, December 2nd, Andrew Dudum sold 33,513 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.38, for a total transaction of $1,118,663.94.
• On Tuesday, November 5th, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.88, for a total transaction of $3,943,981.44.

Hims & Hers Health Stock Up 4.0 %

Hims & Hers Health stock opened at $30.90 on Friday. The firm has a fifty day moving average of $27.98 and a 200-day moving average of $22.09. Hims & Hers Health, Inc. has a 52-week low of $8.51 and a 52-week high of $35.02. The firm has a market capitalization of $6.75 billion, a P/E ratio of 70.22 and a beta of 1.31.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same quarter in the prior year, the business earned ($0.04) earnings per share. The company’s revenue was up 77.1% compared to the same quarter last year. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP lifted its position in shares of Hims & Hers Health by 34.5% during the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock worth $63,446,000 after purchasing an additional 883,230 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Hims & Hers Health by 12.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock worth $79,029,000 after buying an additional 482,177 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in Hims & Hers Health by 164.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock worth $10,663,000 after buying an additional 328,142 shares in the last quarter. Carnegie Investment Counsel purchased a new position in Hims & Hers Health in the 3rd quarter valued at about $5,531,000. Finally, Blueshift Asset Management LLC grew its stake in shares of Hims & Hers Health by 834.8% during the third quarter. Blueshift Asset Management LLC now owns 245,013 shares of the company’s stock valued at $4,513,000 after acquiring an additional 218,804 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. BTIG Research initiated coverage on Hims & Hers Health in a research note on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target on the stock. Morgan Stanley started coverage on Hims & Hers Health in a research report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 target price on the stock. Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their price target for the stock from $32.00 to $18.00 in a research note on Thursday, November 14th. TD Cowen reissued a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Finally, Citigroup cut shares of Hims & Hers Health from a “neutral” rating to a “sell” rating and lifted their target price for the stock from $24.00 to $25.00 in a research report on Friday, January 10th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Hims & Hers Health has an average rating of “Hold” and an average price target of $25.13.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.